For individuals with advanced NSCLC lacking driver gene mutations and PD-L1 expression greater than 1%, particularly those with PD-L1 expression exceeding 50%, the recommendation is to consider PD-1/PD-L1 inhibitor monotherapy or combination chemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.